| 000 | 01499 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250517232645.0 | ||
| 264 | 0 | _c20190612 | |
| 008 | 201906s 0 0 eng d | ||
| 022 | _a2468-2942 | ||
| 024 | 7 |
_a10.1016/j.ctarc.2017.11.003 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBillingsley, Caroline C | |
| 245 | 0 | 0 |
_aIs it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis. _h[electronic resource] |
| 260 |
_bCancer treatment and research communications _c2018 |
||
| 300 |
_a21-25 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aFebrile Neutropenia _xchemically induced |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFilgrastim _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xadministration & dosage |
| 650 | 0 | 4 | _aPrimary Prevention |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 | _aRisk Factors |
| 700 | 1 | _aCohn, David E | |
| 700 | 1 | _aCrim, Aleia K | |
| 700 | 1 | _aLi, Quan | |
| 700 | 1 | _aO'Malley, David M | |
| 700 | 1 | _aHavrilesky, Laura J | |
| 773 | 0 |
_tCancer treatment and research communications _gvol. 14 _gp. 21-25 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ctarc.2017.11.003 _zAvailable from publisher's website |
| 999 |
_c28726274 _d28726274 |
||